Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
" @/ y( T0 ]5 DNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
, c% p# }" b% b/ W1 C4 h, \* Y M+ Author Affiliations
( M, j7 _* ~, m0 E; F I
8 s1 }! w+ k2 o/ m* i! B1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ! F5 c/ j" T: j- u
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
- p# S- X8 W3 Y# K; s7 b5 ^3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
* r: p; v' |. Z* b; E; O$ D4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
) N1 p+ _' r0 z" Z5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
0 b& O$ x- |" c" d, p2 [6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
0 U/ Q2 @0 I$ b2 P: W+ A6 F7Kinki University School of Medicine, Osaka 589-8511, Japan ' |7 V% b" g: d; `% c' C
8Izumi Municipal Hospital, Osaka 594-0071, Japan ' f9 z" z) C8 J: D. ]
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
4 c5 u( w$ m" {. S$ _- r2 Q! tCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp / h% N9 s& g5 V" F8 {+ z( q
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
4 n, z" b+ H0 o2 G: m
& \, r0 M8 s: E) u3 D* S7 ]3 G0 H |